Oasmia
  1. Home
  2. About Oasmia
  3. Human Health
  4. Animal Health
  5. Investor Relations
  6. Media Contact
  7. Work at Oasmia
 Home · Contact · Dictionary · Sitemap

Sitemap

Further reading Frontpage

Human Health

Further reading Clinical Studies
Further reading Links
Further reading Products
Further reading Resultat

Animal Health

Further reading Clinical Studies
Further reading Links
Further reading Products

Investor relations

Further reading Analys
Further reading Calendar
Further reading Reports
Further reading The share
Further reading Ägare

Pages

Further reading About Oasmia
Further reading Animal Health
Further reading Board of Directors
Further reading Contact information
Further reading Dictionary
Further reading For patients
Further reading For pet owners
Further reading For physicians
Further reading For veterinarians
Further reading History
Further reading Human Health
Further reading Investor Relations
Further reading Job vacancies
Further reading Management
Further reading Media contact
Further reading Organization
Further reading Production
Further reading Produkter Animal Health
Further reading Research and development
Further reading Studier Human
Further reading Vanliga frågor
Further reading Visions & goals

Press releases

Further reading “Jackpot in sight for Oasmia”
Further reading Final advice for Paclical Phase III program
Further reading Great interest for Oasmia in Budapest
Further reading Interim report May 2007 - Jan 2008
Further reading New drug for treatment of cancer in dog
Further reading New license agreement with Orion Corporation
Further reading Oasmia announces licensing agreement
Further reading OASMIA confirms Orphan Drug Designation
Further reading Oasmia in Barcelona
Further reading Oasmia obtains Orphan Drug designation
Further reading Oasmia presented in Florida
Further reading Oasmia presents in Budapest
Further reading Oasmia presents in USA
Further reading Oasmia presents Phase III-results in Denmark
Further reading Oasmia publishes Listing Prospectus
Further reading Oasmia to NGM Equity
Further reading Phase III results presented in Copenhagen
Further reading Status – listing of Oasmia
Further reading Unique results for cancer drug
Further reading Very good clinical results for Paclical®

Information from Oasmia

Further reading Interim report 2006-10-31
Oasmia Pharmaceutical AB, Vallongatan 1, SE-752 28 Uppsala, Sweden
Telephone +46 18 50 54 40 Fax +46 18 51 08 73 E-mail info@oasmia.com